Isis Pharmaceuticals Initiates Phase 2 Study Of Isis-FXI Rx In Patients With End-Stage Renal Disease On Hemodialysis, Isis  Will Be Eligible To Receive $55M Payment from Bayer Upon Completion of Study, Advancement of Program